We are live on
!
Find out more
RCMNY
Rubric Capital Management (New York) Portfolio holdings
AUM
$9.44B
1-Year Est. Return
68.42%
This Fund
S&P 500
This Quarter
Est. Return
+1.19%
1 Year Est. Return
+68.42%
3 Year Est. Return
+212.09%
5 Year Est. Return
+270.59%
10 Year Est. Return
–
AUM
$1.99B
AUM Growth
+$81.5M
(+4.3%)
Cap. Flow
+$144M
Cap. Flow
% of AUM
7.26%
Top 10 Holdings %
Top 10 Hldgs %
40.54%
Holding
101
New
13
Increased
27
Reduced
12
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mativ Holdings
MATV
|
+$56.2M |
| 2 |
Noble Corp
NE
|
+$42.9M |
| 3 |
DEN
Denbury Inc.
DEN
|
+$42.8M |
| 4 |
Green Plains
GPRE
|
+$34.6M |
| 5 |
Dole
DOLE
|
+$28.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RDUS
Radius Health, Inc.
RDUS
|
+$72.2M |
| 2 |
Greif
GEF
|
+$37.4M |
| 3 |
Insmed
INSM
|
+$25.4M |
| 4 |
BRSL
Brightstar Lottery PLC
BRSL
|
+$23.9M |
| 5 |
IEA
Infrastructure and Energy Alternatives, Inc. Common Stock
IEA
|
+$22.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.08% |
| 2 | Industrials | 19.95% |
| 3 | Energy | 18.9% |
| 4 | Financials | 10.05% |
| 5 | Materials | 8.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
EverQuote
EVER
$867M
| $8.5M | 0.43% |
1,246,622
-229,123
| -16% | -$2.15M |
|
52
Ovid Therapeutics
OVID
$489M
| $8.31M | 0.42% |
4,516,300
+1,633,594
| +57% | +$3.42M |
|
53
Sutro Biopharma
STRO
$353M
| $7.77M | 0.39% |
140,000
+50,000
| +56% | +$2.96M |
|
54
TherapeuticsMD
TXMD
$24.1M
| $7.68M | 0.39% |
1,156,953
+365,122
| +46% | +$2.96M |
|
55
FTAI Infrastructure
FIP
$533M
| $7.66M | 0.39% |
+3,193,530
| New | +$9.12M |
|
56
Nerdy
NRDY
$93.7M
| $7.28M | 0.37% |
3,450,406
| – | – |
|
57
Cullinan Oncology
CGEM
$1.26B
| $7.18M | 0.36% |
559,737
+262,390
| +88% | +$3.54M |
|
58
Laureate Education
LAUR
$5.1B
| $6.92M | 0.35% |
+655,482
| New | +$7.43M |
|
59
PLAYSTUDIOS Inc
MYPS
$72.1M
| $6.84M | 0.34% |
1,961,184
| – | – |
|
60
Krystal Biotech
KRYS
$9.85B
| $6.46M | 0.33% |
92,609
| – | – |
|
|
ETNB
61
DELISTED
89bio
ETNB
| $5.73M | 0.29% |
+989,388
| New | +$4.35M |
|
62
Tarsus Pharmaceuticals
TARS
$3.07B
| $4.88M | 0.25% |
284,732
+82,084
| +41% | +$1.3M |
|
63
AtaiBeckley Inc
ATAI
$2.68B
| $4.37M | 0.22% |
1,319,137
| – | – |
|
64
Werewolf Therapeutics
HOWL
$18.6M
| $4.36M | 0.22% |
966,879
+761,883
| +372% | +$4.14M |
|
65
MediaAlpha
MAX
$787M
| $4.26M | 0.21% |
486,910
-147,669
| -23% | -$1.44M |
|
|
VIRX
66
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $4.25M | 0.21% |
+994,801
| New | +$4.21M |
|
67
AvePoint
AVPT
$2.75B
| $4.08M | 0.21% |
1,017,539
-2,212,626
| -68% | -$10.4M |
|
68
Advantage Solutions
ADV
$399M
| $4.03M | 0.2% |
75,583
| – | – |
|
|
TSVT
69
DELISTED
2seventy bio
TSVT
| $3.86M | 0.19% |
265,000
| – | – |
|
70
Theravance Biopharma
TBPH
$878M
| $3.61M | 0.18% |
+356,100
| New | +$3.34M |
|
|
XOMA
71
DELISTED
Xoma
XOMA
| $3.6M | 0.18% |
200,785
+51,339
| +34% | +$1.06M |
|
72
CytomX Therapeutics
CTMX
$760M
| $3.49M | 0.18% |
2,406,449
| – | – |
|
73
Precision BioSciences
DTIL
$205M
| $3.45M | 0.17% |
88,571
| – | – |
|
|
VINC
74
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
| $2.91M | 0.15% |
105,350
| – | – |
|
|
TVRD
75
Tvardi Therapeutics
TVRD
$22.1M
| $2.5M | 0.13% |
7,416
| – | – |
|
Similar funds
RCM
SIM
NPT
AC
PVI
WPL
LAMI
CCMT
Rubric Capital Management (New York)'s Q3 2022 Portfolio in Review
As of Q3 2022, Rubric Capital Management (New York) held 101 positions worth $1.99B, up 4.3% from $1.9B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Rubric Capital Management (New York) deployed $144M of net new capital in Q3 2022, opening 13 new positions and adding to 27 existing holdings. Its largest new stake was Mativ Holdings: 2,456,759 shares worth $54.2M.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, up from 23% a quarter earlier, followed by Industrials and Energy.
On the sell side, the largest reduction was Hertz, an estimated $13.8M trimmed.
- Rubric Capital Management (New York)'s largest Q3 2022 buy was Mativ Holdings: 2,456,759 shares worth $54.2M.
- Rubric Capital Management (New York) added most to Mr. Cooper in Q3 2022, an estimated $19.1M increase.
- Rubric Capital Management (New York)'s biggest Q3 2022 reduction was Hertz, cutting an estimated $13.8M.
- Rubric Capital Management (New York) fully exited Radius Health, Inc. in Q3 2022, selling an estimated $72.2M.
- Rubric Capital Management (New York)'s ten largest holdings make up 41% of its $1.99B portfolio in Q3 2022.
- Rubric Capital Management (New York) opened 13 new positions and closed 14 in Q3 2022.
- Rubric Capital Management (New York)'s portfolio value rose 4.3% quarter-over-quarter to $1.99B.
Based on Rubric Capital Management (New York)'s 13F filing for Q3 2022, filed 14 Nov 2022.